{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral SARS-CoV-2 mRNA vaccination sensitizes tumors to anti-PD-L1 checkpoint blockade in murine models.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        },
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "Findings in mouse models may not translate to all human tumors."
    },
    {
      "claim_id": "C02",
      "claim": "A broader peptide repertoire appears on MHC-I after vaccination, improving tumor visibility to T cells.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        },
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination",
          "line_ref": "L28"
        }
      ],
      "caveat": "Antigen presentation changes are shown in mice and may vary by tumor type."
    },
    {
      "claim_id": "C03",
      "claim": "Retrospective human analysis associates prior mRNA vaccination with better survival under ICI treatment.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "Retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.",
          "line_ref": "L15"
        }
      ],
      "caveat": "The analysis is retrospective and likely confounded, limiting causal claims."
    },
    {
      "claim_id": "C04",
      "claim": "Blocking type I interferon signaling eliminates the sensitization benefit seen with mRNA vaccination.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        },
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "The mechanistic chain is described in specific models and may differ in other settings."
    }
  ]
}
